<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906330</url>
  </required_header>
  <id_info>
    <org_study_id>V1 11.12. 2020 (C.I.R.E.C.)</org_study_id>
    <secondary_id>IS003208</secondary_id>
    <nct_id>NCT04906330</nct_id>
  </id_info>
  <brief_title>Onco-liq: Kit for Breast Cancer Diagnosis.</brief_title>
  <official_title>Onco-liq: Kit for Breast Cancer Diagnosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Nacional del Cáncer, Argentina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Onco-liq is a novel diagnosis kit for early breast cancer detection in blood based in liquid&#xD;
      biopsies and microRNAs. This innovative kit will allow improving the accuracy of cancer&#xD;
      diagnosis which will impact on health, reducing the patient mortality and health costs.&#xD;
&#xD;
      To develop this kit, it has been finished the preclinical PHASE I: in laboratory animals;&#xD;
      PHASE II: exploratory clinical phase for the discovery of candidate biomarkers in breast&#xD;
      cancer patients and PHASE III: clinical validation of biomarkers showing that Onco-liq has&#xD;
      95% specificity.&#xD;
&#xD;
      Currently it is been setting up a &quot;pilot test&quot; for breast cancer to enrol 500 woman&#xD;
      volunteers without previous cancer diagnosis that go to the annual medical control. The&#xD;
      results of the pilot test will give the accuracy for breast cancer early diagnosis and the&#xD;
      management of Onco-liq positive patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">January 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>miRNA levels in plasma</measure>
    <time_frame>Day 1</time_frame>
    <description>miRNA levels in plasma will be determined by RT-qPCR using ΔΔCT method.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>PPHM-0000-21</arm_group_label>
    <description>50-70 year old female patients, without a personal history of oncological pathology, who attend for gynecological and mammographic control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Onco-liq: kit for breast cancer diagnosis.</intervention_name>
    <description>Onco-liq is a novel diagnosis kit for early breast cancer diagnosis in blood, based on liquid biopsies and miRNAs. The main advantage of this kit is that miRNAs released from the tumor into the bloodstream can be detected in the plasma of patients even when the tumor is undetectable by other methods.</description>
    <arm_group_label>PPHM-0000-21</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The plasma from participants will be obtained by centrifugation of blood collected with EDTA,&#xD;
      and retained in a -80 ° C freezer exclusively for laboratory use and under lock and key.&#xD;
      Samples will be codified and labelled.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients, without a personal history of oncological pathology, who attend for&#xD;
        gynecological and mammographic control.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women patients performing gynecological control&#xD;
&#xD;
          -  Between 50-70 years old&#xD;
&#xD;
          -  Without personal history of oncological disease&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who don´t meet the inclusion criteria.&#xD;
&#xD;
          -  Active infection with SARS-CoV-2 (COVID-19).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana De Siervi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IBYME-CONICET</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adriana De Siervi, PhD</last_name>
    <phone>+54 911 3269-5832</phone>
    <email>adrianadesiervi@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juana Moro, MD</last_name>
    <phone>+54 9 11 5181-3320</phone>
    <email>morojuana@gmail.com</email>
  </overall_contact_backup>
  <link>
    <url>https://www.infobae.com/sociedad/2020/08/22/como-es-el-innovador-kit-argentino-que-promete-detectar-el-cancer-de-mama-y-el-de-prostata-antes-que-los-analisis-tradicionales/</url>
    <description>Notice in a local online newspaper</description>
  </link>
  <link>
    <url>https://youtu.be/MeSAcWYHiEU</url>
    <description>Notice in a local TV-news program</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich</investigator_affiliation>
    <investigator_full_name>Adriana De Siervi</investigator_full_name>
    <investigator_title>Ph.D.; Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Liquid biopsy, breast cancer, early diagnosis, microRNAs.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

